Attenuating the defeminization of the neonatal rat brain: mechanisms of action of cyproterone acetate, 1,4,6-androstatriene-3,17,-dione and a synthetic progestin, R5020.
D000733:Androstatrienes / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn / Q000502:physiology; D001923:Brain Chemistry / Q000187:drug effects*; D003534:Cyproterone / Q000494:pharmacology*; D004958:Estradiol / Q000032:analysis / Q000494:pharmacology; D005260:Female; D008297:Male; D009649:Norpregnadienes / Q000494:pharmacology*; D011187:Posture; D045167:Progesterone Congeners / Q000494:pharmacology*; D011397:Promegestone / Q000494:pharmacology*; D051381:Rats / Q000502:physiology*; D011960:Receptors, Estrogen; D012733:Sex Differentiation / Q000187:drug effects*; D012726:Sexual Behavior, Animal / Q000187:drug effects; D013739:Testosterone / Q000097:blood
D000733:Androstatrienes; D009649:Norpregnadienes; D045167:Progesterone Congeners; D011960:Receptors, Estrogen; C011658:androsta-1,4,6-triene-3,17-dione; D013739:Testosterone; D004958:Estradiol; D011397:Promegestone; D003534:Cyproterone